 BASKING RIDGE, N.J., Jan. 06, 2021 GLOBE NEWSWIRE -- Caladrius Biosciences, Inc. Nasdaq: CLBS Caladrius or the Company, a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Companys President and CEO, will participate in the following virtual investor conferences during January 2021. 